CR10014A - DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES. - Google Patents
DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES.Info
- Publication number
- CR10014A CR10014A CR10014A CR10014A CR10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A
- Authority
- CR
- Costa Rica
- Prior art keywords
- alquilazetidina
- heterocicles
- derivatives
- substituted
- receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos novedosos de la fórmula estructural (I) son antagonistas y/o agonistas inversos del receptor cannabinoide-1 (CB1) y son útiles en el tratamiento, prevención y supresión de enfermedades mediadas por el receptor CB1. Los compuestos de la presente invención son útiles como fármacos que actúan a nivel central en el tratamiento de psicosis, deficiencias de la memoria, trastornos cognitivos, enfermedad de Alzheimer, migraña, neuropatía, trastornos neuroinflamatorios que incluyen esclerosis múltiple.Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the cannabinoid-1 receptor (CB1) and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as drugs that act centrally in the treatment of psychosis, memory deficiencies, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuroinflammatory disorders that include multiple sclerosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74018305P | 2005-11-28 | 2005-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10014A true CR10014A (en) | 2008-07-29 |
Family
ID=37779312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10014A CR10014A (en) | 2005-11-28 | 2008-05-22 | DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1954692A1 (en) |
| KR (1) | KR20080073721A (en) |
| AR (1) | AR058199A1 (en) |
| BR (1) | BRPI0619018A2 (en) |
| CR (1) | CR10014A (en) |
| DO (1) | DOP2006000261A (en) |
| EC (1) | ECSP088477A (en) |
| IL (1) | IL191586A0 (en) |
| MA (1) | MA30086B1 (en) |
| NO (1) | NO20082919L (en) |
| PE (1) | PE20070647A1 (en) |
| RU (1) | RU2008126248A (en) |
| SV (1) | SV2009002917A (en) |
| TW (1) | TW200804317A (en) |
| WO (1) | WO2007062193A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| CA2703465A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| WO2012031220A2 (en) | 2010-09-03 | 2012-03-08 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2766349B1 (en) | 2011-03-08 | 2016-06-01 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805818B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2805810B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION |
| FR2805817B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION |
| KR20060019587A (en) * | 2003-06-11 | 2006-03-03 | 머크 앤드 캄파니 인코포레이티드 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| US20090306037A1 (en) * | 2005-05-02 | 2009-12-10 | Merck & Co., Inc. | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/en unknown
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/en not_active Application Discontinuation
- 2006-11-22 TW TW095143274A patent/TW200804317A/en unknown
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/en not_active Ceased
- 2006-11-22 EP EP06838347A patent/EP1954692A1/en not_active Withdrawn
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/en not_active IP Right Cessation
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/en not_active Withdrawn
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/en not_active Application Discontinuation
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/en unknown
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/en not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/en unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/en not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/en unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200804317A (en) | 2008-01-16 |
| WO2007062193A1 (en) | 2007-05-31 |
| ECSP088477A (en) | 2008-06-30 |
| IL191586A0 (en) | 2008-12-29 |
| EP1954692A1 (en) | 2008-08-13 |
| AR058199A1 (en) | 2008-01-23 |
| PE20070647A1 (en) | 2007-08-11 |
| SV2009002917A (en) | 2009-02-19 |
| RU2008126248A (en) | 2010-01-10 |
| MA30086B1 (en) | 2008-12-01 |
| NO20082919L (en) | 2008-08-27 |
| DOP2006000261A (en) | 2007-07-15 |
| BRPI0619018A2 (en) | 2016-11-29 |
| KR20080073721A (en) | 2008-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR7432A (en) | ACTIVE REPLACED AMIDAS OF THE CANABINOID RECEIVER-1 | |
| NI201100084A (en) | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS. | |
| DK2049529T3 (en) | Substituted diazepan-orexin receptor antagonists | |
| NI200900193A (en) | OREXIN RECEPTOR PYRIDYL PIPERIDINE ANTAGONISTS | |
| ATE394400T1 (en) | BICYCLIC ANILIDE SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS | |
| CR20130214A (en) | ANTIGONISTS OF THE RECEIVER OF THE CGPR OF PIPERIDINONA CARBOXAMIDA AZAINDANO | |
| CY1111977T1 (en) | PEPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS HIGHLY DISTRIBUTED DOPAMIN COMPONENTS 2 | |
| AR036302A1 (en) | ASSOCIATION OF A CB1 RECEIVER ANTAGONIST WITH A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND ITS USE IN THE TREATMENT OF PARKINSON'S DISEASE | |
| ATE535514T1 (en) | CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | |
| DE602005020655D1 (en) | Carboxamide-spirolactam CGRP Receptor Antagonists | |
| MX2020013085A (en) | Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof. | |
| MX2009005712A (en) | Substituted diazepan compounds as orexin receptor antagonists. | |
| ATE516803T1 (en) | ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | |
| ATE493412T1 (en) | SPIROHYDANTOIN-ARYL-CGRP RECEPTOR ANTAGONISTS | |
| UA100974C2 (en) | Substituted diazepan compounds as orexin receptor antagonists | |
| ATE537170T1 (en) | CGRP RECEPTOR ANTAGONISTS | |
| CL2008002506A1 (en) | Compounds derived from substituted benzimidazole, preparation process, pharmaceutical composition, useful in the treatment of diseases modulated with antagonists of the fxr receptor, in particular for the treatment of increased levels of lipids and / or cholesterol, atherosclerotic disease, diabetes, cancer, parkinson's , Alzheimer's. | |
| AR036303A1 (en) | ASSOCIATION OF A CB1 RECEIVER ANTAGONIST WITH A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND ITS USE FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| CY1113820T1 (en) | 4-ALKOXYPYRIDAZINE PRODUCER AS HIGHLY DISTRIBUTED DOPAMINE RECEPTOR COMPONENTS 2 | |
| ECSP088477A (en) | DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES | |
| GEAP202115141A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| SV2011003839A (en) | ANTIFUNGIC AGENTS | |
| ATE466853T1 (en) | CGRP RECEPTOR ANTAGONISTS | |
| NZ747778A (en) | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist | |
| CY1122312T1 (en) | 4-HYDROXY-2-PHENYL-4-1,3-THIAZOLE-5-HYLOMETHANONE DERIVATIVES AS TPRM8 ANTAGONISTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |